I-Mab Past Earnings Performance

Past criteria checks 0/6

I-Mab's earnings have been declining at an average annual rate of -14.5%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been declining at an average rate of 36.3% per year.

Key information

-14.5%

Earnings growth rate

66.2%

EPS growth rate

Biotechs Industry Growth	17.0%
Revenue growth rate	-36.3%
Return on equity	-92.9%
Net Margin	-6,110.4%
Last Earnings Update	30 Sep 2024

Recent past performance updates

Recent updates

I-Mab gets Chinese nod to start phase 3 combo treatment trial for myelodysplastic syndrome

Sep 13

I-Mab Biopharma Non-GAAP EPADS of -$1.54, revenue of $7.74M

Aug 30

I-Mab and senior executives may buy $40M worth of shares; stock up 10%

Aug 23

Newsflash: I-Mab (NASDAQ:IMAB) Analysts Have Been Trimming Their Revenue Forecasts

Aug 20

I-Mab doses first patient in phase 1 trial of TJ-CD4B in solid tumors in China

Jul 22

I-Mab Valuation Offers A Biotech Investment Opportunity

Jun 23

Companies Like I-Mab (NASDAQ:IMAB) Are In A Position To Invest In Growth

May 24

I-Mab Shaken By Management Moves, Merger Talk And Delisting Threat

May 06

Bearish: Analysts Just Cut Their I-Mab (NASDAQ:IMAB) Revenue and EPS estimates

Apr 01

I-Mab Founder Retakes Reins In Latest Shakeup Ahead Of Commercialization Phase

Jan 03

I-Mab Gets Boost From Latest Industry Signals On New Cancer Treatment

Oct 14

Revenue & Expenses Breakdown

How I-Mab makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGM:IMAB Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Sep 24	3	-202	67	118
30 Jun 24	3	-206	63	113
31 Mar 24	4	-205	63	113
31 Dec 23	4	-206	64	114
30 Sep 23	-15	-253	77	117
30 Jun 23	-35	-295	79	124
31 Mar 23	-35	-331	94	131
31 Dec 22	-32	-364	118	131
30 Sep 22	-7	-338	118	139
30 Jun 22	18	-344	127	160
31 Mar 22	17	-365	138	180
31 Dec 21	14	-367	142	191
30 Sep 21	247	-103	118	184
30 Jun 21	242	-4	104	176
31 Mar 21	237	34	82	162
31 Dec 20	236	72	62	151
30 Sep 20	0	-140	56	141
30 Jun 20	2	-171	36	144
31 Mar 20	3	-190	64	131
31 Dec 19	4	-213	94	121
30 Sep 19	6	-172	85	97
30 Jun 19	7	-159	91	71
31 Mar 19	8	-111	51	68
31 Dec 18	8	-59	10	62
31 Dec 17	2	-46	4	41

Quality Earnings: IMAB is currently unprofitable.

Growing Profit Margin: IMAB is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: IMAB is unprofitable, and losses have increased over the past 5 years at a rate of 14.5% per year.

Accelerating Growth: Unable to compare IMAB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IMAB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).

Return on Equity

High ROE: IMAB has a negative Return on Equity (-92.94%), as it is currently unprofitable.

I-Mab Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

I-Mab to Report Q3, 2024 Results on Nov 14, 2024

I-Mab to Report First Half, 2024 Results on Aug 28, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

I-Mab to Report First Half, 2023 Results on Aug 17, 2023

First half 2022 earnings: EPS and revenues miss analyst expectations

I-Mab to Report First Half, 2022 Results on Aug 30, 2022

Recent updates

I-Mab Appoints Sean (Xi-Yong) Fu as Chief Executive Officer

I-Mab to Report Q3, 2024 Results on Nov 14, 2024

I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024

I-Mab to Report First Half, 2024 Results on Aug 28, 2024

I-Mab Announces Board and Committee Changes

I-Mab Appoints Phillip Dennis as Chief Medical Officer

I-mab Biopharma (Hangzhou) Co., Ltd. completed the acquisition of I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB).

I-mab Biopharma (Hangzhou) Co., Ltd. completed the acquisition of I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB).

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates upgraded to CN¥12.72 loss

I-Mab: Trading Below Net Cash With Multiple Upside Options

I-mab Biopharma (Hangzhou) Co., Ltd. agreed to acquire I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB) for $80 million.

I-mab Biopharma (Hangzhou) Co., Ltd. agreed to acquire I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB) for $80 million.

I-Mab Announces Board Changes , Effective February 10, 2024

Member of Scientific Advisory Board notifies of intention to sell stock

Chief Legal Officer notifies of intention to sell stock

Price target decreased by 17% to US$21.56

Chief Legal Officer notifies of intention to sell stock

I-Mab and Hi-Bio Announces That the U.S. Food and Drug Administration Has Granted Breakthrough Therapy Designation for Felzartamab, an Investigational Cd38 Antibody, for the Treatment of Primary Memorbranous Nephropathy (PMN)

I-Mab Announces Phase 1 Data of Givastomig at Esmo 2023

I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1Bb Bispecific Antibody Tj-L14b Abl503

New minor risk - Share price stability

Consensus revenue estimates fall by 15%

Consensus revenue estimates fall by 78%

Price target decreased by 19% to US$24.47

I-Mab (NasdaqGM:IMAB) announces an Equity Buyback for $40 million worth of its shares.

I-Mab to Report First Half, 2023 Results on Aug 17, 2023

Member of Scientific Advisory Board notifies of intention to sell stock

I-Mab Announces the Appointment of Raj Kannan as Member of the Board of Directors

TRACON Pharmaceuticals, Inc. Announces Enforcement Action to Collect Binding Arbitration Award from I-Mab Biopharma

Price target increased by 8.5% to US$27.65

Interim CFO notifies of intention to sell stock

Price target increased by 7.2% to US$27.30

Price target decreased by 11% to US$29.81

Price target decreased by 7.7% to US$33.57

We're Keeping An Eye On I-Mab's (NASDAQ:IMAB) Cash Burn Rate

Member of Scientific Advisory Board notifies of intention to sell stock

Price target decreased to US$36.38

Less than half of directors are independent

First half 2022 earnings: EPS and revenues miss analyst expectations

I-Mab Announces Management Changes

I-Mab Announces Executive Changes

I-Mab: Another CD47 Inhibitor Biotech With Great Potential

I-Mab(NasdaqGM:IMAB) dropped from FTSE All-World Index (USD)

I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome

I-Mab gets Chinese nod to start phase 3 combo treatment trial for myelodysplastic syndrome

I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022

Consensus revenue estimates fall by 63%

I-Mab (NasdaqGM:IMAB) announces an Equity Buyback for $40 million worth of its shares.

I-Mab Biopharma Non-GAAP EPADS of -$1.54, revenue of $7.74M

I-Mab and senior executives may buy $40M worth of shares; stock up 10%

Newsflash: I-Mab (NASDAQ:IMAB) Analysts Have Been Trimming Their Revenue Forecasts

I-Mab to Report First Half, 2022 Results on Aug 30, 2022

Consensus revenue estimates fall by 13%

Price target decreased to US$58.94

I-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1Bb Bispecific Antibody TJ-CD4B in Solid Tumors in China

I-Mab doses first patient in phase 1 trial of TJ-CD4B in solid tumors in China

I-Mab Valuation Offers A Biotech Investment Opportunity

Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)

I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin Alfa for Treatment of Pediatric Growth Hormone Deficiency

Price target decreased to US$74.89

I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab

Companies Like I-Mab (NASDAQ:IMAB) Are In A Position To Invest In Growth

I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab

I-Mab Shaken By Management Moves, Merger Talk And Delisting Threat

I-Mab Reportedly Exploring Possible Sale Amid Takeover Interest

Consensus revenue estimates fall by 32%

Price target decreased to US$87.94

Bearish: Analysts Just Cut Their I-Mab (NASDAQ:IMAB) Revenue and EPS estimates